
    
      All subjects who participated in the primary study, in which they received either 2 or 3
      doses of GSK Biologicals hepatitis B vaccine, and who consented to participate in the
      long-term follow-up at Month 42 were contacted by the investigators.

      No additional subjects will be recruited during this long-term follow-up study and no vaccine
      will be administered.
    
  